Phio.jpg
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
November 03, 2023 12:00 ET | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
nouscom logo.png
Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome
October 31, 2023 09:01 ET | Nouscom Srl
Lynch Syndrome is a common hereditary condition associated with a genetic predisposition to and high-risk of developing colorectal and other cancersPhase 1b trial evaluating NOUS-209 monotherapy in...
Immatics Final logo (R)_white_background.png
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
October 24, 2023 07:00 ET | https://immatics.com/
  RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 18, 2023 07:00 ET | EvolveImmune
EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023
Phio.jpg
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 12, 2023 11:00 ET | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio.jpg
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
October 11, 2023 07:30 ET | Phio Pharmaceuticals Corp.
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of...
Immatics Final logo (R)_white_background.png
Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt
September 11, 2023 07:00 ET | Immatics N.V.
Kollaboration kombiniert führende Technologien zur Entwicklung bahnbrechender, in vivo exprimierter mRNA TCER®-MoleküleDie Unternehmen werden zur Entwicklung neuartiger Krebsimpfstoffe Immatics...
Immatics Final logo (R)_white_background.png
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023 07:00 ET | https://immatics.com/
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s...
Phio.jpg
Phio CEO to Speak at Wainwright Conference in New York in September
September 06, 2023 07:30 ET | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to...
Phio.jpg
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
August 21, 2023 07:30 ET | Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...